Эффективность устекинумаба у ребенка с питириазом красным волосяным отрубевидным и патогенным вариантом гена CARD14: клинический случай.
Nikolay N. Murashkin,
Mariya A. Leonova,
Alexandr I. Materikin,
Roman V. Epishev,
Dmitry V. Fedorov,
Roman A. Ivanov,
Ekaterina S. Pavlova,
Leonid A. Opryatin https://doi.org/10.15690/vsp.v24i4.2936
Abstract
Background. Few cases of pityriasis rubra pilaris (PRP) associated with CARD14 gene variants have been reported among pediatric patients in the literature. The inefficacy of standard treatment methods necessitates management with genetically engineered biologic drugs for off-label indications. Case description. 5-year-old child with PRP and pathogenic variant in the CARD14 gene was administered with ustekinumab, genetically engineered biologic drug, for off-label indication due to inefficacy of previous therapy with topical glucocorticoids (methotrexate and acitretin). High efficacy of this therapy was noted. No side effects have been reported. Conclusion. Genetically engineered biologic therapy with ustekinumab can be suggested in the recommended regimen in patients with PRP and pathogenic variant in the CARD14 gene in case of inefficacy of topical glucocorticoids, methotrexate, oral retinoids, and tumor necrosis factor alpha inhibitors.
Supporting agencies: Not specified.
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Mariya A. Leonova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Alexandr I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Roman V. Epishev
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Dmitry V. Fedorov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Ekaterina S. Pavlova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
References
1. Joshi TP, Duvic M. Pityriasis rubra pilaris: An update rewiew of clinical presentation, etiopathogenesis and treatment options. Am J Clin Dermatol. 2024;25(2):243-59. doi: https://doi.org/10.1007/ s40257-023-00836-x
2. Сraiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018;79(3): 487–494. doi: https://doi.org/10.1016/j.jaad.2018.02.034
3. Greiling TM, Brown F, Syed HA. Pityriasis Rubra Pilaris. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
4. Bertin J, Wang L, Guo Y, et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membraneassociated guanylate kinase (MAGUK) family members that interact with BCL 10 and activate NF-kappa B. J Biol Chem. 2001;276(15):11877–11882. doi: https://doi.org/10.1074/jbc.M010512200
5. Zhou T, Al Muqrin A, Abu-Hilal M. Updates on pityriasis rubra pilaris: A scoping review. J Cutan Med Surg. 2024;28(2):158–166. doi: https://doi.org/10.1177/12034754231223159
6. Namazova-Baranova LS, Bakulev AL, Murachkin NN, et al. Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):446–450. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2322.
Review
For citations:
Murashkin N.N., Leonova M.A., Materikin A.I., Epishev R.V., Fedorov D.V., Ivanov R.A., Pavlova E.S., Opryatin L.A. Эффективность устекинумаба у ребенка с питириазом красным волосяным отрубевидным и патогенным вариантом гена CARD14: клинический случай. Current Pediatrics. 2025;24(4):273-278. (In Russ.) https://doi.org/10.15690/vsp.v24i4.2936
Views:
2
Email this article 
